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Abstract
We earlier established a model of a persistent viral CNS infection using two week old immunologically normal (genetically
unmodified) mice and recombinant measles virus (MV). Using this model infection we investigated the role of regulatory T
cells (Tregs) as regulators of the immune response in the brain, and assessed whether the persistent CNS infection can be
modulated by manipulation of Tregs in the periphery. CD4
+ CD25
+ Foxp3
+ Tregs were expanded or depleted during the
persistent phase of the CNS infection, and the consequences for the virus-specific immune response and the extent of
persistent infection were analyzed. Virus-specific CD8
+ T cells predominantly recognising the H-2D
b-presented viral
hemagglutinin epitope MV-H22–30 (RIVINREHL) were quantified in the brain by pentamer staining. Expansion of Tregs after
intraperitoneal (i.p.) application of the superagonistic anti-CD28 antibody D665 inducing transient immunosuppression
caused increased virus replication and spread in the CNS. In contrast, depletion of Tregs using diphtheria toxin (DT) in
DEREG (depletion of regulatory T cells)-mice induced an increase of virus-specific CD8
+ effector T cells in the brain and
caused a reduction of the persistent infection. These data indicate that manipulation of Tregs in the periphery can be
utilized to regulate virus persistence in the CNS.
Citation: Reuter D, Sparwasser T, Hu ¨nig T, Schneider-Schaulies J (2012) Foxp3
+ Regulatory T Cells Control Persistence of Viral CNS Infection. PLoS ONE 7(3):
e33989. doi:10.1371/journal.pone.0033989
Editor: Tian Wang, University of Texas Medical Branch, United States of America
Received January 16, 2012; Accepted February 22, 2012; Published March 20, 2012
Copyright:  2012 Reuter et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors thank the Deutsche Forschungsgemeinschaft for financial support. The funder had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jss@vim.uni-wuerzburg.de
Introduction
The role of CD4
+ CD25
+ regulatory T cells (Tregs) in
autoimmune and pathogen-induced immune responses has been
studied intensively during recent years. An important tool was
provided by the discovery of the transcription factor Foxp3
(forkhead box P3) as a marker for Tregs and their suppressive
activity [1,2,3,4]. During acute viral infections depletion of Tregs
was found to prevent the development of exhausted T cells and to
improve the immune response. In addition, transient depletion of
Tregs in several persistent viral infections led to reactivation of
virus-specific T cells and reduction of the virus load [5,6,7,8,9].
The important protective role of Tregs against an overshooting
immune response in the CNS became obvious in animal models of
stroke and experimental autoimmune encephalitis [10,11], and
human immunodeficiency virus-1 (HIV-1)-associated neuro-de-
generation, where they reduce astrogliosis and microglia-mediated
inflammation [12]. Interestingly, some viruses even developed the
strategy to support the expansion of Tregs in order to suppress
anti-viral cytotoxic T cell (CTL) responses and to limit viral
immunopathogenesis [13,14,15,16,17,18]. Defects in regulation of
numbers or the activity of Tregs are also involved in a number of
human autoimmune diseases such as type 1 diabetes, rheumatoid
arthritis, and multiple sclerosis [19].
Viral infections of the brain mostly represent clinically
important, often life-threatening complications of systemic viral
infections. For example, after acute measles, CNS complications
may occur early as acute post-infectious encephalitis, or after years
of viral persistence as subacute sclerosing panencephalitis (SSPE).
Epidemiological studies indicated that the primary MV infection
of SSPE patients takes place predominantly below the age of two
years, when the immune system of the host is still immature and
residual maternal antibodies may be absent or not sufficient for
complete virus neutralization [20,21]. For intracerebral MV
infection of mice, a transgenic human receptor for MV is not
necessarily required, and various infection models exist depending
on the age of the mice, the virus strain, and the infectious dose
[22,23,24,25,26]. As found in genetically unmodified and MV-
receptor transgenic mice, T cells and IFN-c have a critical role for
protection and clearance of virus from the brain [27,28,29,30].
Transient immunosuppression during MV-infection enhanced
virus replication and facilitated persistence [31]. After intranasal
infection of MV-receptor CD150-transgenic mice, a specific
antiviral cellular immune response including an increased
proportion of Foxp3
+ Tregs in the spleen was observed [32].
Although the presence and activity of Tregs has been demon-
strated, their actual role in viral immunosuppression or immuno-
pathogenesis in the brain remains to be elucidated.
Here we investigated the role of Tregs for virus persistence in
the CNS. According to our model, two week old C57BL/6 mice
(an age in which these mice survive infection, while the immune
system is still not fully matured) were intracerebrally infected and
virus persists in a limited number of neurons in most animals for
more than 10 weeks [33]. We expanded and depleted Tregs in the
periphery during the persistent phase of the viral infection, and
investigated whether this can be exploited to modulate the
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33989‘‘hidden’’ CNS infection. Our data indicate that this is indeed the
case and that manipulation of Tregs can be utilized to regulate
virus-specific CD8
+ effector T cells and virus persistence in the
brain.
Results
Regulatory T cells are present predominantly in spleen
and lymph nodes, but at a low frequency also in the
brain
Two week old mice were intracerebrally (i.c.) infected with
10
3 PFU recombinant MV expressing the rodent brain-adapted
haemagglutinin CAMH and eGFP, or, when indicated, the
recombinant MV without eGFP. Both recombinant viruses
(rMV
EdtagEGFP-CAMH and rMV
EdtagCAMH) have the same
distinct tropism for mouse neurons, and infections cause similar
acute and persistent CNS infections [24,33,34,35]. These
recombinant viruses were designated throughout the manuscript
as rMV-green and rMV.
To determine the number of Tregs present in our infection
model in secondary lymphoid organs and the brain, C57BL/6
mice were infected with rMV-green and analyzed 3, 7, 10, 14 and
28 days post infection. Lymphocytes were isolated from 6 draining
cervical lymph nodes (LN), the spleen, and the brain of MV-
infected and control (i.c. injected PBS) animals. The fraction of
CD4
+ CD25
+ Foxp3
+ T cells of all lymphocytes was determined to
be 1.5–3% in the spleen and 4–6% in LN (Fig. 1 A, B) with no
significant difference between infected and control animals. This
corresponds to a total number of Tregs of approximately 1610
6 in
the spleen and 2610
5 in the prepared LN at day 28 post infection.
Only a small statistically not significant number of Foxp3
+ T cells
was detected in the brain, irrespective of the infection (data not
shown). To obtain statistically significant results and to reduce
standard errors caused by the staining procedure, we used
DEREG mice, which express GFP in Foxp3
+ cells. After infection
of these mice with rMV (not expressing GFP), a small but
significant number of GFP
+ cells, approximately 800 per brain,
was detected in the brains, whereas almost no GFP
+ cells were
detected in controls (Fig. 1 C; n=3, P,0.05, two way ANOVA).
Persistent CNS infection is controlled by the immune
system
In order to find out whether Tregs have an influence on the
persistent CNS infection we first expanded and functionally
activated Tregs using the superagonistic anti-CD28 monoclonal
antibody clone D665 (mAb D665) [36]. This mAb, while causing a
transient expansion of the total lymph node and splenic T cell
population, predominantly expands functional CD4
+ Tregs without
causing systemic cytokine release [37]. In order to test the efficiency
of mAb D665 in young mice, we measured Tregs in a preliminary
experiment in uninfected mice 3 days after a single i.p. injection of
100 mg D665 by flow cytometry. The proportion of CD4
+Foxp3
+
Tregs increased in the spleen and lymph nodes approximately 2-
fold (Fig. 2 A; n=4; P,0.01). This result indicated that mAb D665
can be used for expansion of Tregs also in young mice.
For the following experiments, to investigate the effect of mAb
D665 on the persistent viral infection, we applied 100 mg at day 14
and 21 post infection, and analyzed the brains at 28 dpi (Fig. 2 B).
Under these conditions the total number of lymphocytes increased
significantly after D665 treatment in spleen and LN, but not in the
brain (Fig. 2 C). Furthermore, the proportion of Foxp3
+ Tregs
increased significantly (approximately 2-fold, P,0.01) in spleen in
LN (Fig. 2 D). Interestingly, histological analyzes revealed that the
extent of the viral infection increased considerably after D665
treatment. Large clusters and groups of bright GFP-positive
(directly reflecting virus replication) infected neurons emerged in
the brains of these mice (Fig. 3 A). This was in striking contrast to
the brains of untreated mice at 28 dpi, which contain only a
limited number of infected neurons (Fig. 3 B). It is also strikingly
different from brains at 14 dpi, when the treatment with D665
begins. At this time point areas with weak (vanishing) GFP
expression are observed, that represent areas from which virus is
being eliminated (Fig. 3 C). The quantification demonstrated
Figure 1. Detection of regulatory T cells in secondary lymphoid
organs and the brain of C57BL/6 and DEREG mice. Mice were i.c.
infected and analyzed at 3, 7, 10, 14, and 28 dpi as indicated. The
percentages of regulatory CD4
+ Foxp3
+ T cells all lymphocytes in spleen
(A) and draining cervical lymph nodes (CLN) (B) of rMV-green-infected
and PBS-injected (ctrl) animals were determined using C57BL/6 mice.
Foxp3
+ T cells were quantified by flow cytometry after staining with
antibodies to CD25, CD4, and Foxp3, and gating on positive cells. In
brains (C), total cell numbers of Foxp3-GFP
+ Tregs were determined
using of rMV-infected and PBS-injected (ctrl) DEREG mice. Mean values
6 SEM are presented (n=3).
doi:10.1371/journal.pone.0033989.g001
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treated animals in comparison to control animals at 28 dpi (Fig. 3
D, compare lanes 3 and 5; differences were highly significant:
P,0.0001). Two weeks later, at 42 dpi, the number of infected
cells was reduced, but still higher than in control animals (Fig. 3 D,
compare lanes 4 and 6). The data indicate that CD28-mediated
expansion of Tregs in the periphery during the persistent phase of
the viral infection induced a transient release of the viral infection
from immunological control resulting in a dramatic increase of
virus replication and spread in the CNS.
Transient depletion of Tregs stimulates infiltration of
virus-specific T cells into the brain and virus elimination
For the depletion of Tregs we used transgenic mice expressing
the human diphtheria toxin (DT) receptor under the control of the
Foxp3-promoter, which can be treated with DT to eliminate
specifically Foxp3
+ Tregs (DEREG-mice) [38]. To test the activity
of the DT-batch used, adult DEREG mice were in a pilot
experiment treated with DT under standard conditions (1 mgD T
i.p. injected at 6 consecutive days) and analyzed the next day.
Lymphocytes isolated from the spleen and lymph nodes were
analyzed by flow cytometry to demonstrate the successful
depletion of Foxp3
+GFP
+ Tregs by more than 90% (Fig. 4 A).
In order to assess the effect of Treg depletion on virus persistence
in young mice, persistently infected mice were treated at 3
consecutive days (at day 17, 18, and 20 post infection) with 1 mg
DT and analyzed at day 28 post infection (Fig. 4 B). In these mice,
the viral infection was again quantified histologically in subsequent
brain slices through the complete cerebrum as described earlier
[33]. Treg depletion in DEREG
2/+ mice (compared to DT-
Figure 2. Expansion of T lymphocytes with the superagonistic CD28 antibody D665. (A) Two week old uninfected C57BL/6 mice were i.p.
injected with 100 mg mAb D665 or PBS (control) and analyzed 3 days later. Lymphocytes were isolated from the spleen and lymph nodes (12 per
mouse; 6 cervical, 4 axillary and 2 inguinal lymph nodes). FACS dot plot examples for CD4
+ Foxp3
+ T cells in the lymph nodes are shown (left panels:
ctrl and +mAb D665 with percentages of all gated lymphocytes). Right panel: quantitative evaluation of the proportion of Foxp3
+ T cells (percent of
all CD4
+ T cells) in spleen and lymph nodes of D665-treated and control animals (mean values 6 SEM, n=4, P,0.01). (B) Experimental setup used for
the treatment of MV-infected mice with mAb D665. As a control an appropriate volume of PBS was injected. (C) The total number of lymphocytes in
the spleen and draining lymph nodes (LN) (n=3; P,0.01), and total number of percoll-isolated cells in brains of D665-treated and control animals
(n=3). (D) Quantitative evaluation of CD4
+ Foxp3
+ Tregs in the spleen and LN of D665-treated and control animals (percent CD4
+Foxp3
+ cells of all
CD4
+ T cells; n=3, P,0.002 and P,0.02, respectively).
doi:10.1371/journal.pone.0033989.g002
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2/2 mice as control animals) led to a significant
reduction of the number of infected neurons from brains of
persistently infected animals (n=6, P=0.0098; Fig. 4 C).
In order to investigate whether this increase in virus clearance
correlates with the presence of higher numbers of virus-specific
CD8
+ T cells, we first identified T cell receptor recognized
peptides presented by MHC class I of C57BL/6 mice (H-2
b). Two
recognized peptides, D
bMV-H22–30 (RIVINREHL) and D
bMV-
H446–454 (SNHNNVYWL), were identified as effective in stimu-
lating IFN-c synthesis using the ELISPOT assay (data not shown).
MV-specific CD8
+ T cells were then identified by flow cytometry
using MHC class I (H-2D
b) pentamers loaded with the most
effective peptide MV-H22–30. The percentages of D
bMV-H22–30-
specific CD8
+ T cells in spleen, LN, and the brain were
determined after 3, 7, 10, 14 and 28 days post infection.
Considerable proportions of D
bMV-H22–30-pentamer-positive
CD8
+ T cells were detected in the brain at 7, 10, 14, and
28 dpi (Fig. 5 A). Interestingly, high percentages of D
bMV-H22–30-
specific CD8
+ T cells are present in the brain during the persistent
phase of the infection (at 28 dpi approximately 18% of all CD8
+ T
lymphocytes). Mock-treated animals (i.c. PBS injection; ctrl) did
not contain virus-specific CD8
+ T cells. After treatment of
DEREG mice with DT, the number of Tregs decreased by
approximately 95%, while the number of CD8
+ T cells in brains
slightly increased (Fig. 5 B). Interestingly, after depletion of Tregs,
the fraction and absolute number of D
bMV-H22–30-specific CD8
+
T cells increased from 2,000 to 8,000 cells per brain, or 5% to
23% of CD8
+ T cells (n=3, P=0,05; Fig. 5 C). Thus, depletion of
Tregs during the persistent phase of infection led to an increase of
virus-specific CD8
+ T cells and a significant reduction of the
persistent infection in the brain.
Discussion
Our results indicate that the immune system keeps the ‘‘hidden’’
persistent viral CNS infection under permanent control. Manip-
ulation of Tregs in the periphery had significant consequences for
the fate of the viral infection in the brain, although only few
infected neurons are present during the persistent phase of the
infection. Expanding the number of Tregs by superagonistic CD28
antibody D665 led to an activation of virus replication and
dramatic increase of the number of infected neurons, whereas
transient depletion of Tregs by DT led to a significant reduction of
the number of infected neurons. Interestingly, complete elimina-
tion of virus and clearance of the infection was not achieved by
transient depletion of Tregs suggesting that additional means of an
antiviral immune response are required for complete clearance.
Looking for Tregs in the brain, we did not detect a significant
number of CD4
+ Foxp3
+ Tregs by FACS-analysis after staining
with Foxp3-specific antibodies, and only a small number of GFP-
Figure 3. Expansion of T lymphocytes with the superagonistic
CD28 antibody D665 induces virus replication and spread.
Consecutive coronal brain sections (100 mm sections) were prepared
from complete rMV-green-infected mouse cerebra and analyzed using
the UV microscope. Overviews and details of a typical section of an
infected brain of a mouse treated with mAb D665 and analyzed at
28 dpi (A), and sections of infected control animals in the absence of
mAb D665 at 28 dpi (B), and 14 dpi (C) are shown. The numbers of
infected eGFP
+ cells per brain (sections through the complete cerebrum
of each animal were evaluated as described [33]) were determined
microscopically in infected control C57BL/6 mice at 7, 14, 28 and 42 dpi
(D, lanes 1–4) and in D665-treated mice at 28 and 42 dpi (D, lanes 5 and
6). The difference between control and D665-treated mice at 28 dpi was
highly significant (P,0,0001).
doi:10.1371/journal.pone.0033989.g003
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+ cells in infected DEREG mice. These findings
suggest that only very few Tregs,if anyatall,arerequired withinthe
brain for the regulation of effector immune cells, and that this
regulation predominantly takes place in secondary lymphoid
organs. Sellin et al. observed an increase of Foxp3
+ Tregs as a
consequence of MV infection of CD150-transgenic mice in spleen
and brain [32], which suggests that also the MV-infection itself
supports the expansion and migration of Tregs, and that these
infection-induced Tregs may be part of the multifactorial MV-
induced immunosuppression[3,4]. Tregs canrestrain effector T cell
responses through the production of immunomodulatory cytokines,
such as TGF-b, IL-10, and IL-35, expression of inhibitory ligands,
such as CTLA-4 and LAG-3, cytokine consumption, and direct
cytolysis. It remains to be elucidated which of these mechanisms are
involved in the persistent brain infection with MV.
Severalreports support theview that T cellsplay a decisive role in
control of viral CNS infections. Using primary human lymphocytes,
in vitro experiments demonstrated that CD8
+ T lymphocytes control
the dissemination of MV [39]. In resistant mouse strains the
depletion of the CD4
+ T cell subset by monoclonal antibodies led to
a breakdown of resistance to the infection, whereas depletion of
CD8
+ T cells had no effect [23,40]. In TAP-transporter deficient
mice, which cannot present antigen on MHC class I molecules, MV
was found to spread more transneuronally than in brains of normal
mice [41]. These findings indicated that infected neurons are target
cells of CD8
+ lymphocytes, and that brain infections to some extent
can be inhibited by CTL activity. Further investigations revealed
that CD4
+ T cells are able to protect either alone (in resistant mouse
strains), or through cooperation with CD8
+ T cells (in mice with
intermediate susceptibility), and that CD8
+ T cells are able to
protect alone after immunization of the mice [42,43]. Using CD46-
transgenic Rag-deficient mice, adoptive transfer of lymphocytes
revealed that the combined activity of CD4
+ T lymphocytes with
CD8
+ T cells or B cells is required to control the intracerebral
infection [44]. Thus, most findings support the view that CD8
+ T
cells play an important role in the control of transneuronal virus
spread, and our findings suggest that MV-specific CD8
+ T cells are
involved in maintaining the steady state and control of infection
during the persistent phase of CNS infection.
Materials and Methods
Animal infection and manipulation of the frequency of
Tregs
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Figure 4. Depletion of Tregs leads to a reduction of the CNS infection. (A) Adult DEREG (DEREG
2/+) mice were i.p. injected with 1 mg
diphtheria toxin (DT) or with an appropriate volume of PBS (ctrl) at 6 consecutive days and analyzed the next day. Lymphocytes were isolated from
the spleen and LN (6 cervical, 4 axillary, and 2 inguinal). FACS dot plot examples for regulatory CD4
+ Foxp3-GFP
+ T cells in the lymph nodes (left
panels), and a quantitative evaluation of Foxp3-GFP
+ T cells (percentage of all lymphocytes, right panel) from spleen and LN (mean values 6 SEM,
n=4, P,0.01) are shown. (B) Experimental setup for the treatment of young MV-infected DEREG mice with DT at day 17, 18, and 20 post infection
and analysis at 28 dpi. (C) Quantitative evaluation of the number of infected eGFP
+ cells at 28 dpi in DEREG (DEREG
2/+) and control (DEREG
2/2) mice
both infected i.c. with rMV-green and treated with DT. The reduction of mean values from 50 to 8 was significant, with P=0,0098. The number of
infected eGFP
+ cells per brain was determined by microscopic evaluation of 100 mm sections through the complete cerebrum as described [33].
doi:10.1371/journal.pone.0033989.g004
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protocol was approved by the Committee on the Ethics of Animal
Experiments of the University of Wu ¨rzburg (Permit Number:
55.2-2531.01-67/06). Specific pathogen free C57BL/6 mice were
purchased from Harlan-Winkelmann, Germany. DEREG mice
[38] were breeded in the animal facilities of the Institute for
Virology and Immunobiology and the Centre for Experimental
Medicine, Wu ¨rzburg. Mice were anesthetized using isofluran and
infected intracerebrally (i.c.) into the left hemisphere with 20 ml
virus suspension containing 1610
3 PFU at an age of two weeks.
To expand Tregs, mice were treated intraperitoneally (i.p.) with
100 mg superagonistic anti-CD28 monoclonal antibody (mAb)
D665 [36], and to deplete Tregs, DEREG mice were treated i.p.
with 1 mg diphtheria toxin (DT; Merck) [38].
Cell lines and viruses
Vero cells (African green monkey; ATCC CRL 6318) were
cultured in Eagle’s minimal essential medium (MEM) containing
5% fetal calf serum (FCS), 100 U/mL penicillin and 100 mg/mL
streptomycin. Recombinant measles viruses expressing the rodent
adapted haemagglutinin of the strain CAM/RB (CAMH) and/or
not the enhanced green fluorescent protein (eGFP) rMV
Edtag
EGFP-CAMH (rMV-green) and rMV
EdtagCAMH (rMV) [35,45]
were propagated using Vero cells.
Histology
For analyzes, animals were anesthetized with CO2 and perfused
with 4% (w/v) paraformaldehyde (PFA). Brains were fixed in 4%
PFA at least 18 h, and free-floating sections (100 mm) were
prepared using a vibratome (Technical Products International) as
described [33,35]. Slices were analyzed directly by UV microsco-
py. Photomicrographs were taken with a digital camera (Leica).
Numbers of infected eGFP-positive neurons were counted and
statistical analyzes done using the student’s t test and the program
Prism (GraphPad, Inc.).
Isolation of lymphocytes from lymph nodes, the spleen,
and the brain
Draining cervical lymph nodes and the spleen were pressed
through a steel sieve in 4 ml HBSS and homogenized in a total
volume of 13 ml HBSS. After a centrifugation step at 310 g for
10 min the cell pellets were resuspended in an adequate volume of
HBSS (approximately 10
7/cells/ml). Spleen cells were additionally
treated with erythrocyte lysis buffer (155 mM NH4Cl, 10 mM
KHCO3, 0.1 mM EDTA) and washed with HBSS. Brains were
pressed through a steel sieve in 5 ml HBSS 3% FCS and
homogenized in a total volume of 20 ml HBSS 3% FCS. After a
centrifugation step at 170 g for 10 min the cell pellet was
resuspended in 1.4 ml dissociation buffer (23 mM CaCl2,
50 mM KCl, 42 mM MgCl2, 153 mM NaCl) containing 0.4 U
collagenase (Serva) and 50 U Benzonase (Novagen) and incubated
at 37uC for 1 h. Afterwards the cells were washed with HBSS and
applied on a percoll density gradient to separate the lymphocytes
from the rest like myelin debris or neuronal cells as described [46].
The lymphocytes were isolated and washed to remove the percoll
for subsequent analyzes.
Antibodies and flow cytometry
Monoclonal fluorescein-isothiocyanat (FITC)-, phycoerythrin
(PE)- or peridinin chlorophyll protein (PerCP)-conjugated anti-
Figure 5. Treg depletion causes an increase in virus-specific CD8+ T cells in the brain. (A) The proportion of virus-specific D
bMV-H22–30-
pentamer
+ CD8
+ T cells of all CD8
+ T cells was determined in spleen, lymph nodes, and brains of MV-infected C57BL/6 mice at days 3, 7, 10, 14, and 28
post infection (n=3). MV-specific cells were gated as CD19-negative lymphocytes to exclude pentamer
+ CD19
+ cells. The total number of CD8
+ T cells
(B) and the number and proportion of D
bMV-H22–30-pentamer
+ CD8
+ T cells (C) was determined in brains of 28 days infected control (DEREG
2/2) and
DEREG (DEREG
2/+) mice, both treated with DT (Values 6 SEM; n=3).
doi:10.1371/journal.pone.0033989.g005
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Ly-2)-, CD19 (clone 1D3)- and CD25 (clone 7D4)-antibodies were
purchased from Becton Dickinson. PE-conjugated anti-mouse
Foxp3 (clone FJK-16s)-antibody was purchased from NatuTec.
Lymphocytes were stained in FACS buffer (PBS containing 0.4%
BSA and 0.02% sodium azide) at 4uC for 20 min. Intracellular
staining of Foxp3 was performed using the Foxp3 Staining Buffer
Set (NatuTec) according to the manufacture’s protocol. Briefly,
cells were fixed and permeabilized in 500 ml fixation/permeabi-
lization buffer (Concentrate/Diluent 1:4) at RT for 1 h and
stained afterwards in permeabilization buffer at RT for 30 min.
Flow cytometric analysis was performed on a FACSCalibur
(Becton Dickinson).
Selection of MHC class I presented peptides
For identification of peptides presented by MHC class I that can
be used in ELISPOT and pentamer staining experiments we used
the software programs SYFPEITHI (University of Tu ¨bingen,
Germany) and BIMAS (BioInformatics and Molecular Analysis
Section, National Health Instituts, Bethesda, USA) to establish a
ranking of potential peptides. From 12 potential H-2 K
b and D
b–
presented peptides of MV-N and MV-H with the highest
probability scores, we found that D
bMV-H22–30 and D
bMV-
H446–454 (RIVINREHL and SNHNNVYWL, respectively) were
most efficiently recognized. ELISPOT experiments were per-
formed using the Mouse IFN-c ELISPOT set (BD Biosciences)
according to the manufacture’s protocol.
Pentamer staining
MHC class I (H-2D
b) pentamers presenting the selected peptide
MV-H22–30 (D
bMV-H22–30–pentamers) were ordered from
ProImmune Ltd (Oxford, UK). Cells were washed with FACS
buffer and stained with 5 mL pentamer-solution diluted in 100 ml
FACS buffer at 4uC for 30 min. After one washing step the cells
were analyzed using the FACSCalibur. MV-specific cells were
gated as CD8
+ and CD19-negative lymphocytes to exclude
pentamer
+ CD19
+ cells.
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